Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Marcelo V. Negrao"'
Autor:
Pasi A, Jänne, Gregory J, Riely, Shirish M, Gadgeel, Rebecca S, Heist, Sai-Hong I, Ou, Jose M, Pacheco, Melissa L, Johnson, Joshua K, Sabari, Konstantinos, Leventakos, Edwin, Yau, Lyudmila, Bazhenova, Marcelo V, Negrao, Nathan A, Pennell, Jun, Zhang, Kenna, Anderes, Hirak, Der-Torossian, Thian, Kheoh, Karen, Velastegui, Xiaohong, Yan, James G, Christensen, Richard C, Chao, Alexander I, Spira
Publikováno v:
The New England journal of medicine. 387(2)
Adagrasib, a KRASIn a registrational phase 2 cohort, we evaluated adagrasib (600 mg orally twice daily) in patients withAs of October 15, 2021, a total of 116 patients withIn patients with previously treated
Autor:
Lixia Diao, Esra A. Akbay, Linghua Wang, Won-Chul Lee, Kwok-Kin Wong, Don L. Gibbons, Luisa M. Solis Soto, Ruiping Wang, Stephen G. Swisher, Jing Wang, Runzhe Chen, Roohussaba Khairullah, You Hong Fan, Alexandre Reuben, Mingrui Zhu, Jack A. Roth, Boris Sepesi, Irene Guijarro Munoz, John V. Heymach, Carmen Behrens, Jianhua Zhang, Jacqulyne P. Robichaux, Marcelo V. Negrao, Humam Kadara, Edwin R. Parra, Monique B. Nilsson, Lorenzo Federico, Tatiana Karpinets, Ignacio I. Wistuba, Chantale Bernatchez, Jianjun Zhang, Daniel J. McGrail, S. Patel, Xiuning Le, Ara A. Vaporciyan, Yasir Elamin, Cara Haymaker, Jun Li, Lauren Averett Byers
Publikováno v:
Journal of Thoracic Oncology. 16:583-600
Introduction Lung adenocarcinomas harboring EGFR mutations do not respond to immune checkpoint blockade therapy and their EGFR wildtype counterpart. The mechanisms underlying this lack of clinical response have been investigated but remain incomplete
Autor:
Chang-Jiun Wu, Ximing Tang, David H. Peng, Marcelo V. Negrao, Aik Choon Tan, Kazutaka Fukumura, Stephen G. Swisher, John V. Heymach, Jing Wang, Xin Hu, Latasha Little, Alexandre Reuben, Jianhua Zhang, Anthony San Lucas, Kenichi Suda, Jianjun Zhang, Ali Jalali, P. Andrew Futreal, Won-Chul Lee, Shawna M Hubert, Emily Roarty, Marcus Coyle, Erik P. Sulman, Ganesh Rao, Carmen Behrens, Jason T. Huse, Rebecca Thornton, Neda Kalhor, Jihye Kim, Xingzhi Song, Don L. Gibbons, Runzhe Chen, Whijae Roh, Chia Chin Wu, Chi-Wan Chow, Daniel R. Gomez, Lixia Diao, Chad Tang, Wei Lu, Jun Li, Curtis Gumbs, Nicholas McGranahan, Junya Fujimoto, J. Jack Lee, Paul Scheet, Ignacio I. Wistuba
Publikováno v:
Genome Biology, Vol 21, Iss 1, Pp 1-21 (2020)
Genome Biology
Genome Biology
Background Metastasis is the primary cause of cancer mortality accounting for 90% of cancer deaths. Our understanding of the molecular mechanisms driving metastasis is rudimentary. Results We perform whole exome sequencing (WES), RNA sequencing, meth
Autor:
Xiuning Le, Lingzhi Hong, Chuck Hensel, Rongrong Chen, Haley Kemp, Niamh Coleman, Christine A. Ciunci, Stephen V. Liu, Marcelo V. Negrao, Jennifer Yen, Xuefeng Xia, Juergen Scheuenpflug, Christopher Stroh, Dilafruz Juraeva, Anne Tsao, David Hong, Victoria Raymond, Paul Paik, Jianjun Zhang, John V. Heymach
Publikováno v:
JCO Precision Oncology
PURPOSE MET exon 14 skipping alterations ( METex14) comprise a diverse set of actionable oncogene drivers in non–small-cell lung cancer (NSCLC). Recent studies have established the efficacy of tyrosine kinase inhibitors for this patient population.
Autor:
Maria Laura Rubin, Marcelo V. Negrao, Vincent K. Lam, Jack A. Roth, Vassiliki A. Papadimitrakopoulou, Stephen G. Swisher, John V. Heymach, J. Jack Lee, Waree Rinsurongkawong, Ignacio I. Wistuba, Alexandre Reuben, Jeff Lewis, Don L. Gibbons, Jianjun Zhang, Lara Lacerda Landry, Bonnie S. Glisson, George R. Blumenschein, Emily Roarty
Publikováno v:
Journal of Thoracic Oncology. 14:1021-1031
Introduction Immune checkpoint blockade (ICB) has revolutionized the treatment of NSCLC, but only approximately 15% of patients achieve durable benefit. Understanding mechanisms of resistance to ICB is pivotal in developing more effective treatment s
Autor:
Waree Rinsurogkawong, John V. Heymach, Emily Roarty, Daniel R. Gomez, Lara Lacerda, Jianjun Zhang, Jadi M. Bohac, Jacqulyne P. Robichaux, Stephen G. Swisher, Vassiliki A. Papadimitrakopoulou, Melissa K. Shorter, Jack A. Roth, Jeff Lewis, Mara B. Antonoff, Hai T. Tran, Marcelo V. Negrao, Yasir Elamin, Xiuning Le
Publikováno v:
Clinical Lung Cancer. 20:43-47
Introduction Although most NSCLC patients with sensitizing epidermal growth factor receptor (EGFR) mutations have an impressive initial response, the vast majority has residual disease and develops acquired resistance after 9 to 14 months of EGFR tyr
Autor:
Chun Ng, Caroline E. McCoach, Rebecca J. Nagy, Jacqulyne P. Robichaux, Young Kwang Chae, Victoria M. Raymond, Sai-Hong Ignatius Ou, Jeffrey M. Clarke, Funda Meric-Bernstam, Marcelo V. Negrao, Patrick Kwok Shing Ng, John V. Heymach, Viola W. Zhu, Monique B. Nilsson, Kimberly C. Banks, Emily Roarty, Junqin He, David R. Gandara, Trever G. Bivona, Richard B. Lanman, Bianca E. Amador, Jeffrey Crawford
Publikováno v:
J Thorac Oncol
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 15, iss 10
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol 15, iss 10
IntroductionApproximately 4% of NSCLC harbor BRAF mutations, and approximately 50% of these are non-V600 mutations. Treatment of tumors harboring non-V600 mutations is challenging because of functional heterogeneity and lack of knowledge regarding th
Autor:
Franciele Hinterholz Knebel, Joao Victor Machado Alessi, Artur Katz, Anamaria A. Camargo, Luiz F. L. Reis, Manoel Cruz, Marcelo V. Negrao, Andrea K. Shimada, Fabiana Bettoni
Publikováno v:
Lung Cancer. 108:238-241
Osimertinib is an EGFR-T790M-specific TKI, which has demonstrated impressive response rates in NSCLC, after failure to first-line anti-EGFR TKIs. However, acquired resistance to osimertinib is also observed and the molecular mechanisms of resistance
Autor:
Garrett M. Frampton, Jordi Rodon Ahnert, Huiying Sun, Ting Chen, Lemei Hu, R. S. K. Vijayan, Zane Yang, John V. Heymach, Monique B. Nilsson, Kwok-Kin Wong, Funda Meric-Bernstam, Marcelo V. Negrao, Alexa B. Schrock, Brent Roeck, Junqin He, Cross Jason, Alissa Poteete, Richard B. Lanman, Xiuning Le, Jacqulyne P. Robichaux, Jing Wang, Fahao Zhang, Victoria M. Raymond, Mark J. Routbort, Shuai Li, Marlese Pisegna, Vincent A. Miller, Yasir Elamin, Lee A. Albacker, Lixia Diao, Han Han
Publikováno v:
Cancer Cell
We characterized the landscape and drug sensitivity of ERBB2 (HER2) mutations in cancers. In 11 datasets (n = 211,726), ERBB2 mutational hotspots varied across 25 tumor types. Common HER2 mutants yielded differential sensitivities to eleven EGFR/HER2
Autor:
Xiuning, Le, Sonam, Puri, Marcelo V, Negrao, Monique B, Nilsson, Jacqulyne, Robichaux, Theresa, Boyle, J Kevin, Hicks, Katherine L, Lovinger, Emily, Roarty, Waree, Rinsurongkawong, Ming, Tang, Huiying, Sun, Yasir, Elamin, Lara C, Lacerda, Jeff, Lewis, Jack A, Roth, Stephen G, Swisher, J Jack, Lee, William N, William, Bonnie S, Glisson, Jianjun, Zhang, Vassiliki A, Papadimitrakopoulou, Jhanelle E, Gray, John V, Heymach
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(24)
Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment ofUsing cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung